DAIC

MARCH 7, 2024

Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. vs. 13.2%, respectively).

Heart Failure 105

Heart Failure Biomarkers CMS Reimbursement 105

DAIC

JUNE 4, 2024

To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. I had had a heart attack previously. Stroke recovery is a challenging process that extends for months after hospital discharge.

Stroke 115

Stroke Strokes Innovation Research 115

CardiacWire

MARCH 24, 2024

Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.

Medicare 59

Medicare Obesity CMS Medicaid 59